CLINICAL TRIAL article
Front. Pediatr.
Sec. Pediatric Infectious Diseases
Volume 13 - 2025 | doi: 10.3389/fped.2025.1579006
This article is part of the Research TopicAdvancing pediatric critical care: Sepsis, immune dysregulation, and precision therapiesView all articles
A randomized controlled trial on the efficacy and safety of vitamin A supplementation in children with sepsis
Provisionally accepted
- 1Department of Criticla Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China, Chengdu, Sichuan, P.R.China, China
- 2Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China, Chengdu, Sichuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Our previous research confirmed that vitamin A (VA) deficiency commonly occurs in children with sepsis, and serum VA levels negatively correlate with disease severity. This study aimed to evaluate the efficacy and safety of VA supplementation (VAS) in children with sepsis. Methods A randomized, single-blind, single-center trial was conducted from June 2020 to March 2024 involving children diagnosed with sepsis. Participants were randomly allocated to either the VAS group or the placebo group. The primary outcome was length of stay in the ICU, and secondary outcomes included hospital length of stay, 28day mortality, duration of mechanical ventilation, and antibiotic usage. Vital signs, clinical symptoms, and laboratory data were recorded, and statistical analyses assessed the efficacy and safety of VAS. Results A total of 156 children with sepsis were enrolled: 72 in the VAS group and 84 in the placebo group. The median baseline VA level among participants was 147.22 (97.20-258.04) ng/ml. There was no significant difference in ICU length of stay 1 † Contributed equally
Keywords: Sepsis, Vitamin A, PICu, Lactate, albumin, Inflammation
Received: 05 Mar 2025; Accepted: 23 Jul 2025.
Copyright: © 2025 Fu, Liu, Xuepeng, Fu, Zhang, Ji and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Siyuan Chen, Department of Criticla Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China, Chengdu, Sichuan, P.R.China, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.